Summary
Synopsis
Pravastatin is an HMG-CoA reductase inhibitor which lowers plasma cholesterol levels by inhibiting de novo cholesterol synthesis.
Pravastatin produces consistent dose-dependent reductions in both total and low density lipoprotein (LDL)-cholesterol levels in patients with primary hyper-cholesterolaemia. Favourable changes in other parameters such as total triglyceride and high density lipoprotein (HDL)-cholesterol levels are generally modest. Combination therapy with other antihyperlipidaemic agents such as cholestyramine further enhances the efficacy of pravastatin in patients with severe dyslipidaemias.
Available data suggest that pravastatin is effective in elderly patients and in patients with hypercholesterolaemia secondary to diabetes mellitus or renal disease.
The benefit of cholesterol-lowering in terms of patient outcomes is currently an area of considerable interest. Recently completed regression studies (PLAC I, PLACII, KAPS and REGRESS) show that pravastatin slows progression of atherosclerosis and lowers the incidence of coronary events in patients with mild to moderately severe hypercholesterolaemia and known coronary heart disease. Large scale primary (WOSCOPS) and secondary (CARE) prevention studies, moreover, demonstrate that pravastatin has beneficial effects on coronary morbidity and mortality. In WOSCOPS, all-cause mortality was reduced by 22%.
Pravastatin is generally well tolerated by most patients (including the elderly), as evidenced by data from studies of up to 5 years in duration. As with other HMG-CoA reductase inhibitors, myopathy occurs rarely (<0.1% of patients treated with pravastatin); approximately 1 to 2% of patients may present with raised serum levels of hepatic transaminases.
Thus, with its favourable effects on cardiovascular morbidity/mortality and total mortality, pravastatin should be considered a first-line agent in patients with elevated cholesterol levels, multiple risk factors or coronary heart disease who are at high risk of cardiovascular morbidity.
Pharmacodynamic Properties
Pravastatin inhibits HMG-CoA reductase, the enzyme which catalyses the rate-limiting step within the cholesterol biosynthetic pathway. By inhibiting de novo cholesterol production and reducing intracellular cholesterol stores, pravastatin stimulates the synthesis and activity of low density lipoprotein (LDL) receptors, thereby enhancing the clearance of atherogenic LDL-cholesterol. In vitro and in vivo data indicate that pravastatin exhibits hepatocellular tissue selectivity, with greatest inhibition of cholesterol synthesis occurring in the liver.
In hypercholesterolaemic patients, pravastatin produces consistent changes in total cholesterol, LDL-cholesterol, high density lipoprotein (HDL)-cholesterol and triglyceride levels; its effects on lipoprotein(a) are, however, variable.
Hypercholesterolaemic patients treated with pravastatin 10 to 20 mg/day also show decreases in apolipoprotein B (the major component of LDL) of 12 to 30%. Other major proteins found in HDL (apolipoprotein AI and AII) increase by 12 to 16%, while apolipoproteins CII, CIII and E [mainly found in chylomicrons and very low density lipoprotein (VLDL)-cholesterol] are reduced by 4 to 8%.
Pravastatin slows the progression of atherosclerosis in humans and may have beneficial effects in stabilising plaques, improving endothelial dysfunction, decreasing platelet thrombus formation, improving fibrinolytic activity and reducing the incidence of transient myocardial ischaemia. The drug appears to have no effect on adrenal and gonadal hormone production, gallstone formation or sleep patterns.
Pharmacokinetic Properties
Pravastatin is administered orally as the sodium salt of the active compound. It is rapidly absorbed with mean peak plasma concentrations (Cmax) occurring between 0.9 and 1.6 hours after single- or multiple-dose administration in hypercholesterolaemic patients. Dose-proportional increases in both Cmax and area under the plasma concentration-time curve were also observed. The drug has an oral bioavailability of 17%.
In healthy volunteers given intravenous pravastatin 10mg, the volume of distribution averaged 0.46 L/kg at steady-state. Approximately 50% of the drug is bound to plasma proteins. Tissue distribution studies in animals have demonstrated that pravastatin is selectively taken up by hepatic cells; negligible distribution into human breast milk has been reported.
The major metabolite of pravastatin, a 3α-hydroxy isomeric compound (SQ 31 906), has approximately one-tenth to one-fortieth of the HMG-CoA reductase inhibitory activity of pravastatin; 75% of the total inhibitory activity of pravastatin is attributable to the parent drug. Pravastatin undergoes extensive first-pass extraction in the liver (extraction ratio 0.66). It is rapidly excreted and has a terminal plasma elimination half-life of 1.3 to 2.6 hours. Approximately 70 and 20% of an oral dose is eliminated in faeces and urine, respectively, over 96 hours. In patients with renal or hepatic insufficiency, these dual routes of elimination may provide compensatory pathways for the excretion of pravastatin.
Clinical Effectiveness
The lipid-lowering efficacy of pravastatin has been well established in several large, controlled clinical trials evaluating patients with primary or secondary hypercholesterolaemia. Recent research has focused on assessing what benefits this has for normo- or hypercholesterolaemic patients with, or at risk of, coronary heart disease (CHD).
Recently completed regression studies (PLAC I, PLAC II, KAPS, REGRESS) show that pravastatin slows the progression of atherosclerosis and lowers the incidence of coronary events in patients with mild to moderately severe hypercholesterolaemia and evident CHD. Long term primary intervention data from WOSCOPS, moreover, demonstrate that pravastatin has beneficial effects on coronary morbidity and mortality, without associated increases in non-cardiovascular mortality. Combined primary end-points of nonfatal myocardial infarction or death from CHD were significantly reduced by 31%; all-cause mortality was lowered by 22%. The risk of recurrent nonfatal myocardial infarctions or death from CHD was also significantly reduced by 24% in patients receiving pravastatin in the CARE study (a secondary intervention trial). Relative reductions in risk were unaffected by age, presence of hypertension or diabetes, gender or smoking status. At present, pravastatin is the only HMG-CoA reductase inhibitor for which primary and secondary prevention data are available.
Combination therapy with other lipid-lowering agents such as cholestyramine, ω-3 fatty acids, gemfibrozil, nicotinic acid (niacin) or probucol enhances the efficacy of pravastatin; coadministration with cholestyramine may, however, negate the beneficial effects on triglycéride levels achieved with pravastatin monotherapy. Although concomitant use of gemfibrozil or nicotinic acid with pravastatin promotes further beneficial changes in both triglyceride and HDL-cholesterol levels, this combination should be used cautiously because of the potential increased risk of myopathy.
The lipid-lowering efficacy of pravastatin in elderly patients appears similar to that observed in younger individuals. Pravastatin has been successfully used in patients with hypercholesterolaemia secondary to other disease states such as diabetes mellitus or renal disease, in patients with hypertension, and in heart and kidney transplant recipients.
Like other HMG-CoA reductase inhibitors, pravastatin is likely to be more cost effective in secondary than in primary prevention, and in higher than in lower risk patient groups. Available pharmacoeconomic data are, however, inconclusive regarding the relative cost-effectiveness of agents within this class of drugs because of the lack of long term clinical outcomes data. Analysis of WOSCOPS and CARE will address some of these issues.
Tolerability
Data from various short and long term (5-year) studies suggest that pravastatin is generally well tolerated by most patients, including the elderly. Commonly reported events include gastrointestinal disturbances and skin rashes.
As with other HMG-CoA reductase inhibitors, myopathy occurs rarely (in <0.1% of patients treated with pravastatin). Concomitant therapy with cyclosporin, gemfibrozil, erythromycin or nicotinic acid may enhance the risk of myopathy in patients receiving HMG-CoA reductase inhibitors. Increases in hepatic transaminases occur in 1 to 2% of patients, and routine monitoring of liver function is indicated. Cataract development and sleep disturbances have not been associated with pravastatin.
The bioavailability of pravastatin was unaffected by concomitant administration with aspirin, antacids (given 1 hour before pravastatin), cimetidine, cholestyramine (given 1 hour after or 4 hours before pravastatin), colestipol (given 1 hour after pravastatin), digoxin, warfarin, probucol or nicotinic acid. Increases in plasma pravastatin concentrations have been observed with concurrent cyclosporin therapy; reductions in pravastatin clearance have also been noted in combination with gemfibrozil.
Dosage and Administration
The recommended adult dosage of pravastatin is generally 10 to 40mg taken once daily at bedtime (or divided into two daily doses). Dosages are usually initiated at 10 to 20 mg/day; in some European countries, starting dosages of 5 mg/day are also advocated. Pravastatin should be titrated according to response at intervals of not less than 4 weeks. Lower dosages may be required in patients with a history of significant renal or hepatic dysfunction, in the elderly or in patients taking concomitant cyclosporin or gemfibrozil. Pravastatin is contraindicated in patients with active liver disease or unexplained increases in hepatic transaminase levels. There are insufficient clinical data to recommend the use of pravastatin in children.
Similar content being viewed by others
References
Gotto AM, LaRosa JC, Hunninghake D, et al. A summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. Circulation 1990; 81: 1721–33
National Cholesterol Education Program. Second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel II). Circulation 1994; 89: 1333–445
O’Connor P, Feely J, Shepherd J. Lipid lowering drugs. BMJ 1990; 300: 667–72
Alberts AW. Effects of HMG CoA reductase inhibitors on cholesterol synthesis. Drug Invest 1990; 2 Suppl. 2: 9–17
McTavish D, Sorkin EM. Pravastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1991; 42: 65–89
Plosker GL, Wagstaff AJ. Fluvastatin: a review of its pharmacology and therapeutic efficacy in hypercholesterolaemia. Drugs 1996; 51: 433–59
ER Squibb & Sons Limited. Pravastatin prescribing information. Middlesex, UK, 1994-5
Tsujita Y, Kuroda M, Shimada Y, et al. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effects on various animal species. Biochim Biophys Acta 1986; 877: 50–60
Amorosa LF, Rozovski SJ, Ananthakrishnan R, et al. Effects of pravastatin on cholesterol metabolism in Watanabe heritable hyperlipidemic rabbits. Jpn Heart J 1992; 33: 451–63
Koga T, Shimada Y, Kuroda M, et al. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-2-methylglutaryl coenzyme A reductase inhibitor. Biochim Biophys Acta 1990; 1045: 115–20
Reihnér E, Rudling M, Ståhlberg D, et al. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med 1990; 323: 224–8
Ziegler K, Stünkel W. Tissue-selective action of pravastatin due to hepatocellular uptake via a sodium-independent bile acid transporter. Biochim Biophys Acta 1992; 1139: 203–9
Yamazaki M, Suzuki H, Hanano M, et al. Na+-independent multispecific anion transporter mediates active transport of pravastatin into rat liver. Am J Physiol 1993; 264: G36–44
Mosley ST, Kalinowski SS, Schafer BL, et al. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens. J Lipid Res 1989; 30: 1411–20
De Vries ACJ, Cohen LH. Different effects of the hyperlipidemic drugs pravastatin and lovastatin on the cholesterol biosynthesis of the human ocular lens in organ culture and on the cholesterol content of the rat lens in vivo. Biochim Biophys Acta 1993; 1167: 63–9
De Vries ACJ, Vermeer MA, Bloemendal H, et al. Pravastatin and simvastatin differently inhibit cholesterol biosynthesis in human lens. Invest Ophthalmol Vis Sci 1993; 34: 377–84
Kalinowski SS, Tanaka RD, Mosley ST. Effects of long-term administration of HMG-CoA reductase inhibitors on cholesterol synthesis in lens. Exp Eye Res 1991; 53: 179–86
De Vries ACJ, Vermeer MA, Bredman JJ, et al. Cholesterol content of the rat lens is lowered by administration of simvastatin, but not pravastatin. Exp Eye Res 1993; 56: 393–9
Nakaya N, Homma Y, Tamachi H, et al. The effect of CS-514, an inhibitor of HMG-CoA reductase, on serum lipids in healthy volunteers. Atherosclerosis 1986; 61: 125–8
Pan HY, Willard DA, Funke PT, et al. The clinical pharmacology of SQ 31,000 (CS 514) in healthy subjects. In Paoletti R, editor. Drugs affecting lipid metabolism, Berlin: Springer-Verlag, 1987: 255–9
Pan HY, DeVault AR, Wang-Iverson D, et al. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin. J Clin Pharmacol 1990; 30: 1128–35
Pan HY, Triscari J, De Vault AR, et al. Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. Br J Clin Pharmacol 1991; 31: 665–70
Franceschini G, Cassinotti, M, Vecchio G, et al. Pravastatin effectively lowers LDL cholesterol in familial combined hyperlipidemia without changing LDL subclass pattern. Arterioscler Thromb 1994; 14: 1569–75
Slyper AH. Low-density lipoprotein density and atherosclerosis. JAMA 1994; 272: 305–8
Fieseler H-G, Armstrong VW, Wieland E, et al. Serum Lp(a) concentrations are unaffected by treatment with the HMG-CoA reductase inhibitor pravastatin: results of a 2-year investigation. Clin Chim Acta 1991; 204: 291–300
Hunninghake DB, Stein EA, Mellies MJ. Effects of one year of treatment with pravastatin, an HMG-CoA reductase inhibitor, on lipoprotein a. J Clin Pharmacol 1993; 33: 574–80
Klausen IC, Gerdes LU, Meinertz H, et al. Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration. Eur J Clin Invest 1993; 23: 240–5
Umeda F, Watanabe J, Inoue K, et al. Effect of pravastatin on serum lipids, apolipoproteins and lipoprotein (a) in patients with non-insulin dependent diabetes mellitus. Endocrinol Jpn 1992; 39: 45–50
Roheim PS. Atherosclerosis and lipoprotein metabolism: role of reverse cholesterol transport. Am J Cardiol 1986; 57: 3C–10C
Bard JM, Parra HJ, Douste-Blazy P, et al. Changes in lipoprotein particles defined by their apolipoprotein composition on pravastatin or cholestyramine therapy. J Drug Dev 1990; 3 Suppl. 1: 111–5
Cheung MC, Austin MA, Moulin P, et al. Effects of pravastatin on apolipoprotein-specific high density lipoprotein sub-populations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 1993; 102: 107–19
Kazumi T, Yoshino G, Kasama T, et al. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apolipoproteins in patients with primary hypercholesterolaemia. Horm Metab Res 1986; 18: 654–5
Nakaya N, Goto Y. Effect of CS514 on hypercholesterolemic patients. In Paoletti R, editor. Drugs affecting lipid metabolism, Berlin: Springer-Verlag, 1987: 274–7
Nakaya N, Homma Y, Tamachi H, et al. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects. JAMA 1987; 257: 3088–93
Saito Y, Goto Y, Nakaya N, et al. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects: a double blind test. Atherosclerosis 1988; 72: 205–11
Vega GL, Krauss RM, Grundy SM. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B-containing lipoproteins. J Intern Med 1990; 227: 81–94
Yoshino G, Kazumi T, Iwai M, et al. Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects. Atherosclerosis 1988; 71: 95–101
Franceschini G, Sirtori M, Vaccarino V, et al. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolaemia. J Lab Clin Med 1989; 114: 250–9
Goto Y, Yasugi T, Goto Y, et al. Clinical evaluation of CS-514 (pravastatin) on hyperlipidemia: double blind study with clinofibrate. Clin Evaluation 1988; 16: 211–49
Goto Y, Yamamoto A, Matsuzawa Y, et al. Clinical usefulness of pravastatin (CS-514) in the treatment of patients with hyperlipidemia: double-blind comparison with probucol. J Clin Exp Med 1988; 146: 927–55
Yoshino G, Matsushita M, Iwai M, et al. Two-year study on the effect of pravastatin (CS-514) on plasma lipoprotein and apolipoprotein concentrations in hypercholesterolemic patients. Curr Ther Res 1989; 46: 144–52
Ikeda T, Ochi H, Ohtani I, et al. Comparison of the effects of small doses of probucol and pravastatin on serum lipids and apolipoproteins in nonobese, non-insulin-dependent diabetes mellitus patients with hypercholesterolemia. Curr Ther Res 1992; 51: 593–9
Tawata M, Miwa I, Tsuchiya K, et al. Clinical efficacy of pravastatin for hyperlipidemia in patients with type 2 diabetes mellitus. Arzneimittelforschung 1995; 45: 704–8
Yoshino G, Kazumi T, Iwai M, et al. Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514). Atherosclerosis 1989; 75: 67–72
Kazumi T, Yoshino G, Ishida Y, et al. Long-term efficacy and tolerability of pravastatin in hypercholesterolemia in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 1995; 27: 61–8
Watanabe J, Kobayashi K, Umeda F, et al. Apolipoprotein E polymorphism affects the response to pravastatin on plasma apolipoproteins in diabetic patients. Diabetes Res Clin Pract 1993; 20: 21–7
Tait GW, Shepherd J. Hyperlipidaemia: its pathogenesis, clinical significance and treatment. Pharm J 1989; 242: 134–7
Kume N, Kita T, Mikami A, et al. Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (pravastatin) and cholestyramine. Circulation 1989; 79: 1084–90
Kuroda M, Matsumoto A, Itakura H, et al. Effects of pravastatin sodium alone and in combination with cholestyramine on hepatic, intestinal and adrenal low density lipoprotein receptors in homozygous Watanabe heritable hyperlipidemic rabbits. Jpn J Pharmacol 1992; 59: 65–70
Shiomi M, Watanabe Y, Ito Y, et al. Suppressive effect of the combination treatment with pravastatin sodium and cholestyramine of the progression of atherosclerosis and xanthoma in mature WHHL rabbits. Presented at the 8th International Symposium on Atherosclerosis, 1988 Oct 9–13; Rome, Italy
Hayashi H, Naito C, Ito H, et al. The effect of pravastatin in relation to low density lipoprotein receptor activity. Curr Med Res Opin 1990; 12: 100–7
Khachadurian AK, Shimamura T, Rosovski SJ, et al. Pravastatin decreases serum lipids and vascular cholesterol in Watanabe heritable hyperlipidemic (WHHL) rabbits. Jpn Heart J 1991; 32: 675–85
Shiomi M, Ito T, Tsukada T, et al. Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arterioscler Thromb Vasc Biol 1995; 15: 1938–44
Shiomi M, Ito T, Watanabe Y, et al. Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low. Atherosclerosis 1990; 83: 69–80
Wendelhag I, Wiklund O, Wikstrand J. Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries. Atherosclerosis 1995; 117: 225–36
Levine GN, Keaney JF, Vita JA. Cholesterol reduction in cardiovascular disease. Clinical benefits and possible mechanisms. N Engl J Med 1995; 332: 512–21
Egashira K, Hirooka Y, Kai H, et al. Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994; 89: 2519–24
Kool M, Lustermans F, Kragten H, et al. Does lowering of cholesterol levels influence functional properties of large arteries? Eur J Clin Pharmacol 1995; 48: 217–23
Corsini A, Raiteri M, Soma MR, et al. Simvastatin but not pravastatin has a direct inhibitory effect on rat and human myocyte proliferation. Clin Biochem 1992; 25: 399–400
Davies MJ, Richardson PD, Woolf N, et al. Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993; 69: 377–81
Weissberg PL, Clesham GJ, Bennett MR. Is vascular smooth muscle cell proliferation beneficial? Lancet 1996; 347: 305–7
Corsini A, Mazzotti M, Raiteri M, et al. Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase. Atherosclerosis 1993; 101: 117–25
Corsini A, Raiteri M, Soma MR, et al. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995; 76: 21–8
Onaka H, Hirota Y, Kita Y, et al. The effect of pravastatin on prevention of restenosis after successful percutaneous transluminal coronary angioplasty. Jpn Circ J 1994; 58: 100–6
Yui Y, Kawai C, Hosoda S, et al. Pravastatin (Mevalotin) restenosis trial after percutaneous transluminal coronary angioplasty. Cholesterol reduction rate determines the restenosis rate. Ann NY Acad Sci 1995; 748: 208–16
Sahni R, Maniet AR, Voci G, et al. Prevention of restenosis by lovastatin after successful coronary angioplasty. Am Heart J 1991; 121: 1600–8
Weintraub WS, Boccuzzi SJ, Klein, et al. Lack of effect of lovastatin on restenosis after coronary angioplasty. N Engl J Med 1994; 331: 1331–7
Lacoste LL, Lam JYT, Hung J, et al. Pravachol decreases cholesterol and platelet thrombus formation in coronary patients [abstract no. 73]. Can J Cardiol 1993; 9 Suppl. E: 83E
Lacoste L, Lam JYT, Hung J, et al. Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995; 92: 3172–7
Lacoste L, Lam JYT. Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolaemic coronary patients [abstract no. 1045-19]. J Am Coll Cardiol 1996; 27 Suppl. A: 413A
Mori Y, Noda A, Sakaguchi T, et al. Effect of pravastatin on coagulation and fibrinolytic systems in patients with hypercholesterolemia fin Japanese]. J Kessen Shiketsu 1991; 2: 501–4
Wada H, Mori Y, Kaneko T, et al. Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Ther 1992; 14: 829–34
Barrow SE, Stratton PD, Benjamin N, et al. Reduction of LDL cholesterol by pravastatin does not influence platelet activation in patients with mild hypercholesterolaemia at risk of coronary heart disease. Br J Clin Pharmac 1991; 32: 127–9
Jay RH, Rampling MW, Betteridge DJ. Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment. Atherosclerosis 1990; 85: 249–56
Tsuda Y, Satoh K, Takahashi T, et al. Effect of medication with pravastatin sodium on hemorheological parameters in patients with hyperlipoproteinemia. Int Angiol 1993; 12: 360–4
Tsuda Y, Satoh K, Kitadai M, et al. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996; 122: 225–33
Branchi A, Rovellini A, Sommariva D, et al. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993; 70: 241–3
Dobs AS, Sarma PS, Schteingart D. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Metabolism 1993; 42: 1146–52
Jay RH, Sturley RH, Stirling C, et al. Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia. Br J Pharmacol 1991; 32: 417–22
Ito H. The effects of CS-514 (pravastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipids and steroid hormones in the hypercholesterolemic elderly. J Clin Ther Med 1988; 4: 395–407
Dobs AS, Martin KM, Nazelrod B, et al. Is reduced vitamin D synthesis a complication of treatment with HMG-CoA reductase inhibitors? [abstract]. Arteriosclerosis 1988; 8: 635A
Hoogerbrugge-vd Linden N, de Rooy FWM, Jansen H, et al. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia. Gut 1990; 31: 348–50
Horiuchi I, Ohya T, Tazuma S, et al. Effects of pravastatin (CS-514) on biliary lipid metabolism in patients with hyperlipidemia. Metabolism 1991; 40: 226–30
Kajiyama G, Horiuchi I, Takata K, et al. Effects of CS-514 on biliary lipid metabolism in patients with hyperlipidemia. J Clin Ther Med 1988; 4: 191–200
Tazuma S, Ohya T, Teramen K, et al. Effects of long-term treatment with low-dose pravastatin, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on biliary lipid metastability in patients with hypercholesterolemia [abstract no. 1005]. Hepatology 1993; 18: 308A
Bär PR, Bredman JJ, Koot RW. Simvastatin and lovastatin, but not pravastatin, induce myopathy in young rats [abstract no. 131]. EurJ Clin Invest 1993; 23 Suppl. 1: A24
Fukami M, Maeda N, Fukushige J, et al. Effects of HMG-CoA reductase inhibitors on skeletal muscles of rabbits. Res Exp Med 1993; 193: 263–73
Reijneveld JC, Koot RW, Bredman JJ, et al. Differential effects of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors on the development of myopathy in young rats. Paediatr Res 1996; 39: 1028–35
Smith PF, Eydelloth RS, Grossman SJ, et al. Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cyclosporin A: evaluation in a rat model. Eur Heart J 1992; 13 Suppl. B: 2–6
Harrison RWS, Ashton CH. Do cholesterol-lowering agents affect brain activity? A comparison of simvastatin, pravastatin, and placebo in healthy volunteers. Br J Clin Pharmacol 1994; 37: 231–6
Kamei Y, Shirakawa S, Ishizuka Y, et al. Effect of pravastatin on human sleep. Jpn J Psychiatry Neurol 1993; 47: 643–6
Roth T, Richardson GR, Sullivan JP, et al. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 1992; 15: 426–32
Vgontzas AN, Kales A, Bixler EO, et al. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther 1991; 50: 730–7
Cutler N, Sramek J, Veroff A, et al. Effects of treatment with simvastatin and pravastatin on cognitive function in patients with hypercholesterolaemia. Br J Clin Pharmac 1995; 39: 333–36
Eckernäs S-Å, Roos B-E, Kvidal P, et al. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Br J Clin Pharmac 1993; 35: 284–9
Kostis JB, Rosen RC, Wilson AC. Central nervous system effects of HMG CoA reductase inhibitors: lovastatin and pravastatin on sleep and cognitive performance in patients with hypercholesterolemia. J Clin Pharmacol 1994; 34: 989–96
Partinen M, Pihl S, Strandberg T, et al. Comparison of effects on sleep of lovastatin and pravastatin in hypercholesterolemia. Am J Cardiol 1994; 73: 876–80
Katznelson S, Kobashigawa JA. Dual roles of HMG-CoA reductase inhibitors in solid organ transplantation: lipid lowering and immunosuppression. Kidney Int 1995; 48 Suppl. 52: S112–5
Satoh K, Yamato A, Nakai T, et al. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on mitochondrial respiration in ischaemic dog hearts. Br J Pharmacol 1995; 116: 1894–8
Ichihara K, Satoh K, Abiko Y. Influences of pravastatin and simvastatin, HMG-CoA reductase inhibitors, on myocardial stunning in dogs. J Cardiovas Pharmacol 1993; 22: 852–6
Van Boven AJ, Jukema JW, Zwinderman AH, et al. Pravastatin reduces transient myocardial ischemia in patients with angina pectoris and significant CAD [abstract no. 751–5]. J Am Coll Cardiol 1996; 27 Suppl. A: 165A
Van Boven AJ, Jukema JW, Zwinderman AH, et al. Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris. Circulation 1996; 94: 1503–5
Pan HY, DeVault AR, Swites BJ, et al. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia. Clin Pharmacol Ther 1990; 48: 201–7
Singhvi SM, Pan HY, Morrison RA, et al. Disposition of pravastatin sodium, a tissue selective HMG-CoA reductase inhibitor, in healthy subjects. Br J Clin Pharmacol 1990; 29: 239–43
Sasahara K, Kawabata K. Phase 1 study of CS-514, an inhibitor of HMG-CoA reductase II: pharmacokinetics of CS-514 in healthy volunteers. J Clin Ther Med 1988; 4: 45–65
Pentikainen PJ, Saraheimo M, Schwartz JL, et al. Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans. J Clin Pharmacol 1992; 32: 136–40
Koga T, Kawabata K, Arai K, et al. Comparative pharmacokinetics and pharmacodynamics of pravastatin and simvastatin. Bull Mol Biol Med 1995; 20: 103–5
Pan HY, DeVault AR, Brescia D, et al. Effect of food on pravastatin pharmacokinetics and pharmacodynamics. Int J Clin Pharmacol Ther Toxicol 1993; 31: 291–4
Triscari J, Pan H, De Vault A, et al. Comparative bioavailability of pravastatin following morning and evening dosing [abstract no. PIII-19J. Clin Pharmacol Ther 1991; 49: 178
Hunninghake DB, Mellies MJ, Goldberg AC, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia II. Once-daily versus twice-daily dosing. Atherosclerosis 1990; 85: 219–27
Illingworth DR. Clinical implications of new drugs for lowering plasma cholesterol concentrations. Drugs 1991; 41: 151–60
Pan H, Fleiss P, Moore L, et al. Excretion of pravastatin, an HMG-CoA reductase inhibitor, in breast milk of lactating women. J Clin Pharmacol 1988; 28: 942
Botti RE, Triscari J, Pan HY, et al. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 1991; 14: 256–61
Triscari J, Swanson BN, Willard DA, et al. Steady state serum concentrations of pravastatin and digoxin when given in combination. Br J Clin Pharmacol 1993; 36: 263–5
Tsuji A, Saheki A, Tamai I, et al. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther 1993; 267: 1085–90
Saheki A, Terasaki T, Tamai I, et al. In vivo and in vitro blood-brain barrier transport of 3-hydroxy-3-methyIglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Pharm Res 1994; 11: 305–311
Squibb & Sons, Inc. Pravastatin prescribing information. New Jersey, USA, 1995
Halstenson CE, Triscari J, Devault A, et al. Single-dose pharmacokinetics of pravastatin and metabolites in patients with renal impairment. J Clin Pharmacol 1992; 32: 124–32
Pan HY. Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase. Eur J Clin Pharmacol 1991; 40 Suppl. I: S15–8
Pan HY, Waclawski AP, Funke PT, et al. Pharmacokinetics of pravastatin in elderly versus young men and women. Ann Pharmacother 1993; 27: 1029–33
Betteridge DJ, Dodson PM, Durrington PN, et al. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993; 69: 359–69
Holme I. An analysis of randomized trials evaluating the effect of cholesterol reduction on total mortality and coronary heart disease incidence. Circulation 1990; 82: 1916–24
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–89
McGovern ME, Mellies MJ. Long-term experience with pravastatin in clinical research trials. Clin Ther 1993; 14: 57–64
Frick MH, Elo O, Haapa K, et al. Helsinki heart study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987; 317: 1237–45
Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351–64
Lipid Research Clinics Program. The lipid research clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365–74
Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 1990; 301: 309–14
Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol 1995; 76: 113C–7C
WOSCOPS Study Group. Screening experience and baseline characteristics in the West of Scotland Coronary Prevention Study. Am J Cardiol 1995; 76: 485–91
Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301–7
Shepherd J, Cobbe SM, Ford I. Prevention of coronary heart disease with pravastatin [letter]. N Engl J Med 1996; 334: 1334–5
Pravastatin Multinational Study Group for Cardiac Risk Patients. Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol/liter (200 to 300 mg/dl) plus two additional atherosclerotic risk factors. Am J Cardiol 1993; 72: 1031–7
Pfeffer MA, Sacks FM, Moyé LA, et al. Cholesterol and recurrent events: a secondary prevention trial for normolipidemic patients. Am J Cardiol 1995; 76: 98C–106C
Sacks FM, Rouleau J-L, Moye LA, et al. Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. Am J Cardiol 1995; 75: 621–3
Mellies MJ. Ongoing and planned clinical trials for atherosclerosis prevention and regression. Curr Opin Invest Drugs 1993; 2: 529–39
Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001–9
LIPID Study Group. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris. Am J Cardiol 1995; 76: 474–9
Tonkin AM. Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995;76: 107C–12C
Simes RJ. Prospective meta-analysis of cholesterol-lowering studies: the Prospective Pravastatin Pooling (PPP) project and the Cholesterol Treatment Trialists (CTT) collaboration. Am J Cardiol 1995; 76: 122C–6C
PPP Project Investigators. Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project — a combined analysis of three large-scale randomized trials: Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 1995; 76: 899–905
Byington RP, Jukema JW, Salonen JT, et al. Reduction in cardiovascular events during pravastatin therapy: pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 1995; 92: 2419–25
Salonen R, Nyyssönen K, Porkkala E, et al. Kuopio Atherosclerosis Prevention Study (KAPS): a population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries. Circulation 1995; 92: 1758–64
Pitt B, Ellis SG, Mancini GBJ, et al. Design and recruitment in the United States of a multicenter quantitative angiographie trial of pravastatin to limit atherosclerosis in the coronary arteries (PLAC I). Am J Cardiol 1993; 72: 31–5
Pitt B, Mancini GBJ, Ellis SG, et al. Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC I): reductions in atherosclerosis progression and clinical events. J Am Coll Cardiol 1995; 26: 1133–9
Byington RP, Furberg CD, Crouse JR, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995; 76: 54–9C
Crouse JR, Byington RP, Bond MG, et al. Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC II). Am J Cardiol 1995; 75: 455–9
Barth JD, Zonjee MMB, REGRESS Research Group. Regression growth evaluation statin study (REGRESS): study design and baseline characteristics in 600 patients. Can J Cardiol 1992; 8: 925–32
De Groot E, Jukema JW, van Boven AJ, et al. Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study. Am J Cardiol 1995; 76: 40–6C
Jukema JW, Bruschke AVG, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995; 91: 2528–40
Jukema JW, van Boven AJ, Bal ET, et al. During lipid-lowering therapy or placebo administration progression and regression of coronary lesions occur within the same patient [abstract no. 1217). Eur Heart J 1994; 15 Suppl.: 223
Jukema JW, van Boven AJ, Reiber JHC, et al. Progression and regression of coronary atherosclerosis occur within the same patient during placebo treatment and during lipid-lowering therapy with pravastatin [abstract no. 769-2]. Program and abstracts of original contributions from the 44th Annual Scientific Session American College of Cardiology: 1995 March 19–22: New Orleans, Louisiana, USA; J Am Coll Cardiol (Feb) 1995; 281A
Jukema JW, van Boven AJ, Reiber JHC, et al. Reduction of the beneficial effect of lipid-lowering therapy by pravastatin on coronary atherosclerosis in smoking patients (abstract no. 1584]. Abstracts from the XVIIth Congress of the European Society of Cardiology: 1995 August 20–24: Amsterdam, The Netherlands; Eur Heart J 1995; 16 Suppl.: 273
De Groot E, Jukema JW, Zwinderman AH, et al. Correlations in pravastatin treatment effect between carotid and femoral intima-media thickness, and coronary artery stenosis (abstract 988-22]. J Am Coll Cardiol 1996; 27 Suppl. A: 273A
Furberg CD, Pitt B, Byington RP, et al. Reduction in coronary events during treatment with pravastatin. Am J Cardiol 1995; 76: 60–3C
Sacks FM, Gibson CM, Rosner B, et al. The influence of pretreatment low density lipoprotein cholesterol concentrations on the effect of hypercholesterolemic therapy on coronary atherosclerosis in angiographie trials. Am J Cardiol 1995; 76: 78C–85C
PHYLLIS Project Group. Plaque Hypertension Lipid-Lowering Italian Study (PHYLLIS): a protocol for non-invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. J Hypertens 1993; 11 Suppl. 5: S314–5
Beigel Y, Brook G, Eisenberg S, et al. Efficacy and safety of pravastatin once daily in primary moderate hypercholesterolemia: the Israeli experience. Isr J Med Sci 1993; 29: 272–7
Jacobson TA, Chin MM, Curry CL, et al. Efficacy and safety of pravastatin in African Americans with primary hypercholesterolemia. Arch Intern Med 1995; 155: 1900–6
Rubenfire M, Maciejko JJ, Blevins RD, et al. The effect of pravastatin on plasma lipoprotein and apolipoprotein levels in primary hypercholesterolemia. Arch Intern Med 1991; 151: 2234–40
Hunninghake DB, Knopp RH, Schonfeld G, et al. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia I. A dose-response study. Atherosclerosis 1990; 85: 81–9
Betteridge DJ, Bhatnager B, Bing RF, et al. Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine. BMJ 1992; 304: 1335–8
Wiklund O, Angelin B, Fager G, et al. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels. J Intern Med 1990; 228: 241–7
Arntz HR, Bönner G, Kikis D, et al. Efficacy of pravastatin and bezafibrate in primary hypercholesterolaemia [in German]. Dtsch Med Wochenschr 1991; 116: 7–12
Crepaldi G, Baggio G, Area M, et al. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I. Arch Intern Med 1991; 151: 146–52
Malacco E, Magni A, Scandiani L, et al. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolaemia. Drug Invest 1994; 7: 331–9
Jacotot B, Benghozi R, Pfister P, et al. Comparison of fluvastatin versus pravastatin treatment of primary hypercholesterolaemia. Am J Cardiol 1995; 76: 54A–6A
Kawakami Y, Tagami S, Hasegawa A, et al. Clinical efficacy of fluvastatin (XU62-320) in hyperlipidemia — a comparative study with pravastatin in a double-blind comparative method [in Japanese]. Rinsho Iyaku 1995; 11: 1679–1726
Lovastatin Pravastatin Study Group. A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 1993; 71: 810–5
McPherson R, Bedard J, Connelly P, et al. Comparison of the short-term efficacy and tolerability of lovastatin and pravastatin in the management of primary hypercholesterolemia. Clin Ther 1992; 14: 276–91
Weir MR, Berger ML, Weeks ML, et al. Comparison of the effects on quality of life and of the efficacy and tolerability of lovastatin versus pravastatin. Am J Cardiol 1996; 77: 475–9
European Study Group. Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (Multicountry Comparative Study). Am J Cardiol 1992; 70: 1281–6
Lambrecht LJ, Malini PL, European Study Group. Efficacy and tolerability of simvastatin 20 mg vs pravastatin 20 mg in patients with primary hypercholesterolemia. Acta Cardiol 1993; 48: 541–54
Steinhagen-Thiessen E, Simvastatin Pravastatin European Study Group. Comparative efficacy and tolerability of 5 and 10 mg simvastatin and 10 mg pravastatin in moderate primary hypercholesterolemia. Cardiology 1994; 85: 244–54
Simvastatin Pravastatin Study Group. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993; 71: 1408–14
Illingworth DR, Erkelens WD, Keller U, et al. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin. Lancet 1994; 343: 1554–5
Pravastatin Multicenter Study Group II. Comparative efficacy and safety of pravastatin and cholestyramine alone and in combination in patients with hypercholesterolemia. Arch Intern Med 1993; 153: 1321–9
Jacob BG, Möhrle W, Richter WO, et al. Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia. Eur J Clin Pharmacol 1992; 42: 353–8
Contacos C, Barter PJ, Sullivan DR. Effect of pravastatin and (ω-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia. Arterioscler Thromb 1993; 13: 1755–62
Wiklund O, Angelin B, Bergman M, et al. Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia. Am J Med 1993; 94: 13–20
Davignon J, Roederer G, Montigny M, et al. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 1994; 73: 339–45
O’Keefe JH, Harris WS, Nelson J, et al. Effects of pravastatin with niacin or magnesium on lipid levels and postprandial lipemia. Am J Cardiol 1995; 76: 480–4
Davidson MH, Gwynne JT, Khachadurian AK, et al. Combination of pravastatin and probucol in the treatment of primary hypercholesterolemia. Coron Artery Dis 1991; 2: 1061–8
Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framington study. JAMA 1987; 257: 2176–80
Garber AM, Browner WS, Hulley SB. Cholesterol screening in asymptomatic adults, revisited. Ann Intern Med 1996; 124: 518–31
Krumholz HM, Seeman TE, Merrill SS, et al. Lack of association between cholesterol and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 1994; 272: 1335–40
Bo M, Pernigotti L, Poli L, et al. 1991. One-year experience in the treatment of elderly hypercholesterolemic patients with pravastatin. Curr Ther Res 1991; 50: 151–8
Glasser SP, DiBianco R, Effron BA, et al. The efficacy and safety of pravastatin in patients aged 60 to 85 years with low-density lipoprotein cholesterol > 160 mg/dl. Am J Cardiol 1996; 77: 83–5
Santinga JT, Rosman HS, Rubenfire M, et al. Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemia. Am J Med 1994; 96: 509–15
Mellies MJ, DeVault AR, Kassler-Taub K, et al. Pravastatin experience in elderly and non-elderly patients. Atherosclerosis 1993; 101: 97–110
Chan P, Lee C-B, Lin T-S, et al. The effectiveness and safety of low dose pravastatin in elderly hypercholesterolemic subjects on antihypertensive therapy. Am J Hypertens 1995; 8: 1099–104
Bierman EL. Atherogenesis in diabetes: George Lyman Duff memorial lecture. Arterioscler Thromb 1992; 12: 647–56
Garg A, Grundy SM. Management of dyslipidemia in NIDDM. Diabetes Care 1990; 13: 153–69
Anonymous. Detection and management of lipid disorders in diabetes. Diabetes Care 1993; 16 Suppl. 2: 106–12
Behounek BD, McGovern ME, Kassler KB, et al. A multinational study of the effects of low-dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Clin Cardiol 1994; 17: 558–62
Deerochanawong C, Serirat S. Clinical evaluation of pravastatin in the treatment of type II hyperlipidemia in patients with non-insulin-dependent diabetes mellitus. J Med Assoc Thai 1995; 78: 113–7
Krempf M, Berthezene F, Wemeau JL, et al. Efficacite et tolerance de la pravastatine chez des patients presentant une hypercholesterolemie associee a un diabete de type II [abstract]. Diabete Metab 1993; 19: 44
Raskin P, Ganda OP, Schwartz S, et al. Efficacy and safety of pravastatin in the treatment of patients with type I or type II diabetes mellitus and hypercholesterolemia. Am J Med 1995; 99: 362–9
Sheu WHH, Shieh SM, Shen DDC, et al. Effect of pravastatin treatment on glucose, insulin, and lipoprotein metabolism in patients with hypercholesterolemia. Am Heart J 1994; 127: 331–6
Grundy SM. Management of hyperlipidemia of kidney disease. Kidney Int 1990; 37: 847–53
Spitalewitz S, Porush JG, Cattran D, et al. Treatment of hyperlipidemia in the nephrotic syndrome: the effects of pravastatin therapy. Am J Kidney Dis 1993; 22: 143–50
Tokoo M, Oguchi H, Terashima M, et al. Effects of pravastatin on serum lipids and apolipoproteins in hyperlipidemia of the nephrotic syndrome. Jpn J Nephrol 1992; 34: 397–403
Moorhead JF. Lipids and progressive kidney disease. Kidney Int 1991; 39 Suppl. 31: S35–40
Mori Y, Tsuruoka A. Effect of pravastatin on microalbuminuria in patients with non-insulin-dependent diabetes mellitus [in Japanese]. J Jpn Diabetes Soc 1992; 35: 265–6
Shoji T, Nishizawa Y, Toyokawa A, et al. Decreased albuminuria by pravastatin in hyperlipidemic diabetics. Nephron 1991; 59: 664–5
Alamo C, Aranda JL, Sanchez R, et al. Treatment of proteinuria-related hyperlipidemia with pravastatin [abstract]. Kidney Int 1994; 46: 562
Motellón JL, Sánchez-Tomero A, Gruss E, et al. Treatment with pravastatin of hypercholesterolaemia in nephrological patients: effects on proteinuria and progression of renal failure [abstract]. Nephrol Dial Transplant 1994; 9: 962
Hattori M, Ito K, Kawaguchi H, et al. Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis. Pediatr Nephrol 1993; 7: 196–8
Yoshimura N, Oka T, Okamoto M, et al. The effects of pravastatin on hyperlipidemia in renal transplant recipients. Transplantation 1992; 53: 94–9
Castelao AM, Grinyó JM, Castiñeiras MJ, et al. Effect of pravastatin in the treatment of hypercholesterolemia after renal transplantation under cyclosporine and prednisone. Transplant Proc 1995; 27: 2217–20
Lye WC, Hughes K, Leong SO, et al. Abnormal lipoprotein (a) and lipid profiles in renal allograft recipients: effects of treatment with pravastatin. Transplant Proc 1995; 27: 977–8
Katznelson S, Wilkinson AH, Kobashigawa JA, et al. The effect of pravastatin on acute rejection after kidney transplantation — a pilot study. Transplantation 1996; 61: 1469–74
Schouten JA, Rila H, Gevers Leuven J, et al. Tandem study: efficacy and safety of pravastatin in hypercholesterolemic patients with hypertension [abstract no. 470]. Atherosclerosis 1995; 115 Suppl.: S125
Waeber B, Greminger P, Riesen W, et al. Combined treatment with captopril, hydrochlorothiazide and pravastatin in dyslipidemic hypertensive patients. Blood Press 1995; 4: 358–62
Fogari R, Marasi G, Zoppi A, et al. Effects of pravastatin given every other day in dyslipidemic hypertensives treated with different antihypertensive drugs [abstract no. A62]. Am J Hypertens 1994; 7 (4 Pt 2): 48A
Tsukiyama H, Otsuka K. Effects of pravastatin in dyslipidaemic patients with and without hypertension. J Hypertens 1993; 11 Suppl. 5: S346–7
O’Callaghan CJ, Conway EL, Lam W, et al. Effects of pravastatin on the lipid profile of hypertensive patients receiving captopril [abstract no. 1558]. Am J Hypertens 1993; 6 (5 Pt 2): 109A
Muramatsu J, Kobayashi A, Ikeda Y, et al. Change in cardiac function after long-term treatment of hyperlipidemia by a HMG-CoA reductase inhibitor (pravastatin) in patients with hypertension and ischemic heart disease [abstract no. P979]. Jpn Circ J 1993; 57: 744
Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621–7
Smit JWA, Van Erpecum J, Stolk MFJ, et al. Successful dissolution of cholesterol gallstone during treatment with pravastatin. Gastroenterology 1992; 103: 1068–70
Watanabe M, Takatori Y, Akagi S, et al. Preliminary study on the efficacy of combination therapy with pravastatin and ursodeoxycholic acid (UDCA) in gallstone dissolution [abstract no. 2594P1. World Congress of Gastroenterology, 1994 Oct 2–7; Los Angeles, USA
Smit JWA, Van Erpecum KJ, Renooij W, et al. The effects of the 3-hydroxy, 3-methylglutaryl coenzyme A reductase inhibitor pravastatin on bile composition and nucleation of cholesterol crystals in cholesterol gallstone disease. Hepatology 1995; 21: 1523–9
Kurihara T, Akimoto M, Abe K, et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolaemia. Clin Ther 1993; 15: 890–8
Kawata S, Yamasaki E, Nagase T, et al. Long-term administration of pravastatin, a potent HMG-CoA reductase inhibitor, prolongs survival of patients with advanced hepatocellular carcinoma: a randomized controlled trial [abstract no. 476]. Hepatology 1996; 24 (4 Pt 2): 245A
Pharoah PDP, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996; 312: 1443–8 [letters BMJ 1996; 313: 1142–4]
Reckless JPD. The economics of cholesterol lowering. Baillieres Clin Endocrinol Metab 1990; 4: 947–72
Korman L, Borysiuk L. Replacing lovastatin with pravastatin: effect on serum lipids and costs. Am J Health-Syst Pharm 1995; 52: 1078–82
Smart AJ, Walters L. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors. S Afr Med J 1994; 84: 834–7
Ashraf T, Hay JW, Pitt B, et al. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol 1996; 78: 409–14
Martens LL, Guibert R. Cost-effectiveness analysis of lipidmodifying therapy in Canada: comparison of HMG-CoA reductase inhibitors in the primary prevention of coronary heart disease. Clin Ther 1994; 16: 1052–62 [correspondence Clin Ther 1995; 17:572-80]
Muls E, Van Ganse E, Closon MC. Cost-effectiveness of pravastatin in secondary prevention of CHD: comparison between the US and Belgium of a projected risk model [abstract]. 66th Congress of the European Atherosclerosis Society, 1996 July 13–17; Florence, Italy: 13
Newman TJ, Kassler-Taub KB, Gelarden RT, et al. Safety of pravastatin in long-term clinical trials conducted in the United States. J Drug Dev 1990; 3 Suppl. 1: 275–81
Emmerich J. Comparison of the efficacy, safety and tolerability of simvastatin and pravastatin [letter]. Am JCardiol 1994; 73: 723
Jungnickel PW, Cantral KA, Maloley PA. Relative safety and efficacy of pravastatin [letter]. Clin Pharm 1993; 12: 256–7
Decoulx E, Millaire A, De Groote P, et al. Rhabdomyolysis due to pravastatin and type 1 macrocreatine kinase [in French]. Ann Cardiol Angeiol 1993; 42: 267–9
Hino I, Akama H, Furuya T, et al. Pravastatin-induced rhabdomyolysis in a patient with mixed connective tissue disease. Arthritis Rheum 1996; 39: 1259–61
Perault MC, Ladouch-Bures L, Dejean C, et al. Rhabdomyolyse associée à la prise de pravastatine (Vasten®) [letter]. Therapie 1993; 48: 483–501
Rosenberg AD, Neuwirth MG, Kagen LJ, et al. Intraoperative rhabdomyolysis in a patient receiving pravastatin, a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitor. Anesth Anaig 1995; 81: 1089–91
England JDF, Walsh JC, Stewart P, et al. Mitochondrial myopathy developing on treatment with the HMG CoA reductase inhibitors-simvastatin and pravastatin. Aust NZ J Med 1995; 25: 374–5
Schalke BB, Schmidt B, Touka K, et al. Pravastatin-associated inflammatory myopathy [letter]. N Engl J Med 1992; 327: 649–50
Ballare M, Campanini M, Airoldi G, et al. Hepatotoxic effects of hydroxy-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Ital J Gastroenterol 1991; 23: 281
MacDonald JS, Gerson RJ, Kornbrust DJ, et al. Preclinical evaluation of lovastatin. Am J Cardiol 1988; 62: 16J–27J
Todd PA, Goa KL. Simvastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolaemia. Drugs 1990; 40: 583–607
Behrens-Baumann W, Thiery J, Fieseler HG, et al. Pravastatin — ocular side effects after a two year follow-up? Lens Eye Toxic Res 1990; 7: 311–8
Schmitt C, Schmidt J, Hockwin O. Ocular drug-safety study with the HMG-CoA reductase inhibitor pravastatin. Lens Eye Tox Res 1990; 7: 631–42
Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264: 71–5
Thompson GR. Adverse reactions profile: 10. Simvastatin and pravastatin. Prescr J 1993; 33: 217–20
Garnett WR. Interactions with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am J Health-Syst Pharm 1995; 52: 1639–45
Regazzi MB, Iacona I, Campana C, et al. Altered disposition of pravastatin following concomitant drug therapy with cyclosporin A in transplant recipients. Transplant Proc 1993; 25: 2732–4
Olbricht C, Wanner C, Eisenhauer T, et al. Pravastatin and lovastatin pharmacokinetics and pharmacodynamics in renal transplant patients receiving cyclosporine [abstract]. J Am Soc Nephrol 1995; 6: 1061
Castelao AM, Griñö JM, GilVernet S, et al. Effect of pravastatin in the treatment of hypercholesterolaemia after renal transplantation under cyclosporin immunosuppression. Nephrol Dial Transplant 1993; 8: 1037–8
Davies RA. Safety and efficacy of pravastatin after heart transplantation: preliminary patient studies [abstract]. XI International Symposium on Drugs Affecting Lipid Metabolism, 1992 May 13–16; Florence, Italy: 18
Valino RN, Reiss WG, Hanes D, et al. Examination of the potential interaction between HMG-CoA reductase inhibitors and cyclosporine in transplant patients [abstract no. 139]. Pharmacotherapy 1996; 16: 511
Feher MD, Foxton J, Banks D, et al. Long-term safety of fibrate-statin combination therapy in the treatment of hypercholesterolaemia. Br J Clin Pharmacol 1994; 37: 511P
Rosenson RS, Frauenheim WA. Safety of combined pravastatingemfibrozil therapy. Am J Cardiol 1994; 74: 499–500
Triscari J, Markowitz JS, McGovern MW. Pravastatin and lovastatin in cerebrospinal fluid. Clin Neuropharmacol 1993; 16: 559–60
Trenque T, Choisy H, Germain M-L. Pravastatin: interaction with oral anticoagulant? [letter]. BMJ 1996; 312: 886
Merck & Co, Inc. Simvastatin prescribing information. Pennsylvania, USA, 1995
Merck & Co, Inc. Lovastatin prescribing information. Pennsylvania, USA, 1995
Simons LA, Levis G, Simons J. Apparent discontinuation rates in patients prescribed lipid-lowering drugs. Med J Aust 1996; 164: 208–11
Schucker B, Wittes JT, Santanello NC, et al. Changes in cholesterol awareness and action: results from national physician and public surveys. Arch Intern Med 1991; 151: 666–73
Thelle DS. Epidemiology of hypercholesterolaemia and European management guidelines. Cardiology 1990; 77 Suppl. 4: 2–7
Davey Smith G, Pekkanen J. Should there be a moratorium on the use of cholesterol lowering drugs? BMJ 1992; 304: 431–4
Fey R, Pearson N. Statins and coronary heart disease. Lancet 1996; 347: 1389–90
Rogers S. Prevention of coronary heart disease with pravastatin [letter]. N Engl J Med 1996; 334: 1333
Samani NJ, De Bono DP. Prevention of coronary heart disease with pravastatin [letter]. N Engl J Med 1996; 334: 1333–4
LaRosa JC. Cholesterol-lowering and the cost-effective prevention of recurrent coronary disease. CVR & R 1996; 17: 10–28
Author information
Authors and Affiliations
Corresponding author
Additional information
Various sections of the manuscript reviewed by: M. Aviram, Lipid Research Laboratory, Rambam Medical Center, Haifa, Israel; Y. Beigel, Department of Internal Medicine A, Beilinson Medical Center, Tel Aviv University, Petah Tikva, Israel; J.R. Crouse, Department of Medicine, The Bowman Gray School of Medicine, Winston-Salem, North Carolina, USA; G. Davey Smith, Department of Social Medicine, University of Bristol, Bristol, England; A.M. Gotto Jr, Baylor College of Medicine, Houston, Texas, USA; D.C. Harrison, University of Cincinnati Medical Center, Cincinnati, Ohio, USA; D.R. Illingworth, Department of Medicine, Section of Clinical Nutrition and Lipid Metabolism, Oregon Health Sciences University, Portland, Oregon, USA; L.H. Opie, Heart Research Unit, University of Cape Town Medical School, Cape Town, South Africa; W.H.H Sheu, Division of Endocrinology & Metabolism, Tri-Service General Hospital, Taipei, Taiwan; E. Steinhagen-Thiessen, Universitatsklinikum Rudolf Virchow, Berlin, Germany; G.R. Thompson, MRC Lipoprotein Team, Hammersmith Hospital, London, England; D. Waters, Division of Cardiology, Hartford Hospital, Hartford, Connecticut, USA; O. Wiklund, Wallenberg Laboratory, Sahlgrenska Hospital, Gothenburg, Sweden; N. Yoshimura, Second Department of Surgery, Kyoto Prefectural University of Medicine, Kyoto, Japan
Rights and permissions
About this article
Cite this article
Haria, M., McTavish, D. Pravastatin. Drugs 53, 299–336 (1997). https://doi.org/10.2165/00003495-199753020-00008
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199753020-00008